Insulet Corporation
Clinical trials sponsored by Insulet Corporation, explained in plain language.
A medical device company known for its tubeless insulin pump systems.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Smart insulin pump aims to simplify diabetes management Results expected Dec 2026 (estimated)
- New insulin algorithm aims to simplify diabetes management Results expected Dec 2026 (estimated)
- New insulin pump aims to tame blood sugar swings Results expected Feb 2027 (estimated)
- Thousands to track omnipod 5 in daily life: will the smart pump deliver on its promise? Results expected Jun 2027 (estimated)
- New study puts omnipod 5 to the test in Real-World diabetes management Results expected Jul 2027 (estimated)
-
New insulin algorithm aims to tame type 2 diabetes
Disease control CompletedThis study tested a next-generation automated insulin delivery system in 48 adults with type 2 diabetes aged 16–70. The goal was to see if the smart algorithm could keep blood sugar in a safer range, reducing both low and high blood sugar events. Participants used a continuous gl…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New insulin pump shows promise for type 2 diabetes control
Disease control CompletedThis study tested a wearable insulin pump system (Omnipod M) in 40 adults aged 18-75 with type 2 diabetes. The goal was to see if the system helps keep blood sugar in a safe range and reduces dangerous highs and lows. Participants used the system for 6 weeks, and researchers meas…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Smart insulin pump beats daily shots in diabetes trial
Disease control CompletedThis study tested whether the Omnipod 5, a tubeless automated insulin pump, works better than multiple daily insulin injections for managing type 1 diabetes. 189 children and adults participated. The main goal was to see if the pump improved blood sugar control (HbA1c) over 13 we…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New insulin pump study aims to simplify diabetes management for type 2 patients
Disease control CompletedThis study tested whether a simplified approach to starting automated insulin delivery works safely in adults with type 2 diabetes. 56 participants used the Omnipod M System with a continuous glucose monitor, starting with either a lower or higher insulin dose. The goal was to se…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New smart insulin pump shows promise for diabetes control
Disease control CompletedThis study tested the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 system, an automated insulin pump, in 48 people aged 2 to 70 with type 1 or type 2 diabetes. The system uses a continuous glucose monitor to automatically adjust insulin delivery. The main goals were …
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New insulin pump aims to keep blood sugar in check with fewer mealtime shots
Disease control CompletedThis study compared a new version of the Omnipod insulin pump (SmartAdjust 2.0) to the current Omnipod 5 in 132 people with type 1 or type 2 diabetes, ages 2 to 70. Participants used each system for about a month to see if the new one is safe and helps keep blood sugar in a healt…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Smart insulin pump shows promise for type 2 diabetes control
Disease control CompletedThis study tested the Omnipod 5, a wearable device that automatically delivers insulin, in 343 adults with type 2 diabetes. Participants used the system for 13 weeks to see if it improved blood sugar levels. The goal was to make diabetes management simpler and more effective.
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Automated insulin pump takes on type 1 diabetes in Head-to-Head trial
Disease control CompletedThis study tested the Omnipod 5, an automated insulin delivery system, against standard insulin pumps in 196 adults with type 1 diabetes. Participants used their usual therapy for 14 days, then either switched to Omnipod 5 or stayed on their pump for 90 days. The goal was to see …
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 26, 2026 18:22 UTC